Author(s): Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, et al.
Context: Pneumococcal polysaccharide vaccine is recommended for elderly persons and adults with certain chronic illnesses. Additionally, a recently licensed pneumococcal 7-valent conjugate vaccine has been recommended for use in young children and could dramatically change the epidemiology of pneumococcal disease.
Objectives: To assess pneumococcal disease burden in the United States, estimate the potential impact of new vaccines, and identify gaps in vaccine recommendations.
Design and setting: Analysis of data from the Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network, an active, population-based system in 9 states.
Patients: A total of 15 860 cases of invasive pneumococcal disease occurring between January 1, 1995, and December 31, 1998.
Main outcome measures: Age- and race-specific pneumoccocal disease incidence rates per 100 000 persons, case-fatality rates, and vaccine preventability.
Results: In 1998, overall incidence was 23.2 cases per 100 000, corresponding to an estimated 62 840 cases in the United States. Incidence was highest among children younger than 2 years (166.9) and adults aged 65 years or older (59.7). Incidence among blacks was 2.6 times higher than among whites (95% confidence interval [CI], 2.4-2.8). Overall, 28.6% of case-patients were at least 65 years old and 85.9% of cases in this age group were due to serotypes included in the 23-valent polysaccharide vaccine; 19.3% of case-patients were younger than 2 years and 82.2% of cases in this age group were due to serotypes included in the 7-valent conjugate vaccine. Among patients aged 2 to 64 years, 50.6% had a vaccine indication as defined by the Advisory Committee on Immunization Practices (ACIP). The case-fatality rate among patients aged 18 to 64 years with an ACIP indication was 12.1% compared with 5.4% for those without an indication (relative risk, 2.2; 95% CI, 1.7-2.9).
Conclusions: Young children, elderly persons, and black persons of all ages are disproportionately affected by invasive pneumococcal disease. Current ACIP recommendations do not address a subset of persons aged 18 to 64 years but do include those at highest risk for death from invasive pneumococcal disease.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/11277827
Author(s): Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, et al.
Author(s): Juhn YJ, Kita H, Yawn BP, Boyce TG, Yoo KH, et al.
Author(s): Beard CM, Yunginger JW, Reed CE, O'Connell EJ, Silverstein MD
Author(s): Hunt LW Jr, Silverstein MD, Reed CE, O'Connell EJ, O'Fallon WM, et al.
Author(s): Bauer BA, Reed CE, Yunginger JW, Wollan PC, Silverstein MD
Author(s): Silverstein MD, Yunginger JW, Reed CE, Petterson T, Zimmerman D, et al.
Author(s): Juhn YJ, Sauver JS, Katusic S, Vargas D, Weaver A, et al.
Author(s): Juhn YJ, Weaver A, Katusic S, Yunginger J
Author(s): Juhn YJ, Kita H, Lee LA, Smith RW, Bagniewski SM, et al.
Author(s): Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, et al.
Author(s): Juhn YJ, Kita H, Lee LA, Swanson RJ, Smith R, et al.
Author(s): Laurichesse H, Romaszko JP, Nguyen LT, Souweine B, Poirier V, et al.
Author(s): Smart JM, Kemp AS
Author(s): Fahy JV, Corry DB, Boushey HA
Author(s): Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, et al.
Author(s): Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, et al.
Author(s): Grove DI, Burston TO, Wellby ML, Ford RM, Forbes IJ
Author(s): Lee HJ, Kang JH, Henrichsen J, Konradsen HB, Jang SH, et al.
Author(s): Lahood N, Emerson SS, Kumar P, Sorensen RU
Author(s): Fischer JE, Johnson JE, Kuli-Zade RK, Johnson TR, Aung S, et al.
Author(s): Kincy-Cain T, Clements JD, Bost KL
Author(s): Jung JA, Kita H, Dhillon R, Jacobson RM, Nahm MH, et al.
Author(s): Khan AQ, Shen Y, Wu ZQ, Wynn TA, Snapper CM
Author(s): Iwasaka H, Noguchi T
Author(s): Muret J, Marie C, Fitting C, Payen D, Cavaillon JM